← Back to Search

Monoclonal Antibodies

Atezolizumab for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Led By Thomas Stinchcombe, MD
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This trial will investigate if adding atezolizumab to bevacizumab is a safe and effective treatment for patients with stage 4 EGFR mutant NSCLC whose cancer has progressed while taking osimertinib.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective Response Assessed by the Investigator Using RECIST 1.1
Secondary outcome measures
Number of Participants With AEs as Measured by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03
Overall Survival as Noted by Follow-up Via Composite of Telephone or Medical Record Review.
Progression Free Survival as Measured by RECIST v1.1 RECIST 1.1 (Brand Name) as Assessed by the Investigator.

Side effects data

From 2019 Phase 3 trial • 1225 Patients • NCT02008227
27%
Fatigue
25%
Decreased appetite
24%
Cough
19%
Dyspnoea
19%
Asthenia
18%
Constipation
18%
Pyrexia
18%
Nausea
16%
Diarrhoea
13%
Arthralgia
12%
Vomiting
12%
Anaemia
11%
Back pain
11%
Musculoskeletal pain
11%
Rash
10%
Headache
9%
Oedema peripheral
9%
Weight decreased
9%
Chest pain
9%
Insomnia
9%
Pruritus
9%
Pain in extremity
8%
Dizziness
7%
Upper respiratory tract infection
7%
Aspartate aminotransferase increased
7%
Myalgia
7%
Haemoptysis
6%
Influenza like illness
6%
Nasopharyngitis
6%
Alanine aminotransferase increased
6%
Bronchitis
6%
Productive cough
5%
Musculoskeletal chest pain
5%
Depression
5%
Dry skin
4%
Abdominal pain
4%
Urinary tract infection
4%
Neuropathy peripheral
4%
Paraesthesia
3%
Stomatitis
3%
Dysgeusia
3%
Pneumonia
2%
Malaise
2%
Pleural effusion
2%
Neutropenia
1%
Lacrimation increased
1%
Respiratory tract infection
1%
Sepsis
1%
Pneumonitis
1%
Mucosal inflammation
1%
Bone pain
1%
Pulmonary embolism
1%
Peripheral sensory neuropathy
1%
Alopecia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Atezolizumab
Docetaxel

Trial Design

1Treatment groups
Experimental Treatment
Group I: atezolizumab and bevacizumabExperimental Treatment2 Interventions
Atezolizumab 1200 mg IV every 3 weeks and bevacizumab 15 mg/kg IV every 3 weeks (1 cycle=3 weeks)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atezolizumab
2016
Completed Phase 3
~6040
Bevacizumab
2013
Completed Phase 4
~5280

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,351 Previous Clinical Trials
3,408,837 Total Patients Enrolled
Thomas Stinchcombe, MDPrincipal InvestigatorDuke University
6 Previous Clinical Trials
149 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What other research initiatives have been undertaken to explore Atezolizumab's potential?

"Presently, 621 clinical trials are being conducted on Atezolizumab with 142 in the third phase. Most of these studies take place in Taibei, Taiwan, though there are 31,793 locations around the world where research is taking place."

Answered by AI

Are there any known detrimental effects associated with Atezolizumab treatment?

"Atezolizumab was awarded a safety score of 2 on our team's assessment scale, due to the fact that this is only at Phase 2 and there isn't yet any conclusive evidence for efficacy."

Answered by AI

Are there any vacancies left for prospective participants in this experiment?

"At this moment in time, no more participants are being recruited for this trial. It was first posted on July 9th 2020 and updated as recently as May 23rd 2022. There is an array of alternatives to consider if you are seeking a clinical study; these include 2114 studies recruiting those with disease progression and 621 trials accepting volunteers who have been prescribed Atezolizumab."

Answered by AI

What would Atezolizumab typically be prescribed for?

"Atezolizumab is commonly used to address non-small cell lung carcinoma, recurrent platinum-sensitive ovarian cancer, and postoperative/recurrent occurrences of non-squamous NSCLC."

Answered by AI

How many participants are currently being enrolled for this clinical investigation?

"As of now, this trial is not presently recruiting any more individuals. Initially posted on July 9th 2020 and most recently updated on May 23rd 2022, the study has reached its capacity for recruitment. For anyone else interested in participating in a clinical trial, there are 2114 studies actively enrolling patients with disease progression at present and 621 investigations that seek participants taking Atezolizumab as well."

Answered by AI
~1 spots leftby Mar 2025